Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2024 | Story André Damons | Photo André Damons
Dr Innocensia Mangoato
Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. Here she is with her supervisor and mentor Prof Motlalepula Matsabisa, Director of the University of the Free State (UFS) Department of Pharmacology.

A lecturer and researcher from the University of the Free State (UFS) Department of Pharmacology hopes her research into the use of cannabis in reversing anticancer drug resistance is a step forward into treating various cancers especially in Southern Africa.

Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with the degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. She started her career as a research scientist in the area of African traditional medicines in 2018 and her research received both national and international recognition.

“It’s an amazing (feeling to graduate today). My PhD journey was smooth and beautiful and with mentorship of Prof (Motlalepula) Matsabisa, who groomed me well, I did not shed a tear,” said Dr Mangoato. Dr Gudrun S Ulrich-Merzenich from the University of Bonn in Germany, was her co-supervisor with Prof Matsabisa.

According to the graduation programme, Dr Mangoato, Lecturer and Researcher in the UFS Department of Pharmacology, with her thesis titled Investigating the anticancer and possible resistant reversal effects of cannabis sativa l. extracts in cervical cancer cell lines and modulation of ABC transporters comprehensively explored the therapeutic potential of Cannabis sativa L. in overcoming drug resistance in cervical cancer using in vitro and network pharmacology approaches.

A step forward for treating various cancers

The research looked at the chemical fingerprints and pharmacological targets of C. sativa L. extracts, highlighting its antiproliferative properties against normal non-cancerous cells, cervical cancer cells and the cisplatin-resistant cervical cancer cells. Through PCR analysis, distinct gene expression profiles were identified, revealing the potential effects of combination treatments to counteract cisplatin resistance by downregulating genes associated with drug transporters and crucial signalling pathways. This work provides valuable insights into innovative therapeutic strategies for improving cervical cancer treatment, highlighting new avenues for overcoming resistance and enhancing treatment efficacy though the possible use of plant extracts.

“I hope my research takes a step forward in treating various cancers – especially gynaecology cancers in the Southern Hemisphere in Africa. Hopefully the research can later transcend into clinical trials and hopefully influence more policymakers. We also hope to further develop cannabis to be used as an adjuvant therapy for those drugs that are failing to treat cancer,” says Dr Mangoato, who was the recipient of the Women in Science Master’s Student in 2018.

Her graduation was also a proud moment for Prof Matsabisa, an expert in traditional African medicine, who was like a father to her during her studies. “Prof identified me from my honours degree and walked this journey with me. He has been a great mentor, a father and an amazing supervisor.”

Dr Mangoato says she will for now focus on research only and helping and monitoring upcoming researchers, especially female researchers as there is a scarcity of them her field. 

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept